Universitair Ziekenhuis Brussel
Quick facts
Marketed products
- 300IU rec-LH
- Absence of epidural analgesia
- Epidural analgesia Ropivacaine · Anesthesia/Pain Management
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. - glucose 20% · Endocrinology; Critical Care; Supportive Care
Glucose 20% is a hypertonic dextrose solution that provides rapid carbohydrate substrate for energy metabolism and increases blood glucose concentration. - progesterone 600mg
Phase 3 pipeline
- Taurolidine Urokinase · Infectious Diseases
Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing.
Phase 2 pipeline
- Carboplatinum · Other
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Universitair Ziekenhuis Brussel portfolio CI brief
- Universitair Ziekenhuis Brussel pipeline updates RSS
Frequently asked questions about Universitair Ziekenhuis Brussel
What are Universitair Ziekenhuis Brussel's marketed drugs?
Top marketed products include 300IU rec-LH, Absence of epidural analgesia, Epidural analgesia Ropivacaine, glucose 20%, progesterone 600mg.
What is Universitair Ziekenhuis Brussel's pipeline?
Universitair Ziekenhuis Brussel has 1 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Taurolidine Urokinase.
Related
- 300IU rec-LH
- Absence of epidural analgesia
- Epidural analgesia Ropivacaine · Anesthesia/Pain Management
- glucose 20% · Endocrinology; Critical Care; Supportive Care
- progesterone 600mg
- Sector hub: All tracked pharma companies